Swiss National Bank Prometheus Biosciences, Inc. Transaction History

Swiss National Bank

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	SELL	$103.46 - $126.29 $620,760 - $757,740	-6,000 Reduced 10.7%	50,100 $5.38 Million
Q4 2022 Feb 08, 2023	BUY	$36.06 - $117.21 $1.19 Million - $3.88 Million	33,100 Added 143.91%	56,100 $6.17 Million
Q2 2022 Aug 09, 2022	SELL	$22.39 - $38.94 $102,994 - $179,124	-4,600 Reduced 16.67%	23,000 $649,000
Q1 2022 May 09, 2022	BUY	$30.13 - $50.0 $57,247 - $95,000	1,900 Added 7.39%	27,600 $1.04 Million
Q4 2021 Feb 08, 2022	BUY	$22.28 - $39.54 $572,596 - $1.02 Million	25,700 New	25,700 $1.02 Million

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.